GT MEDICAL TECHNOLOGIES, INC. — SEC Form D Filing

GT MEDICAL TECHNOLOGIES, INC. filed an SEC Form D on July 22, 2026, reporting $50.06M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
July 22, 2026
Amount reported
$50.06M
Round stage
Series B+
Industry
Medical Devices
Website
https://gammatile.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients who undergo surgery for operable brain tumors, including newly diagnosed malignant tumors and recurrent tumors, face significant risks of tumor regrowth and side effects from traditional external radiation therapy.

Solution

GT Medical Technologies develops GammaTile®, an implantable, tile-based radiation therapy that is placed during brain tumor removal surgery to deliver targeted radiation directly to the tumor site, reducing tumor regrowth and minimizing side effects.

Why now

Advances in materials science and targeted radiation delivery allow for novel, localized treatments that improve patient outcomes and quality of life immediately following brain tumor surgery, reducing the burden of traditional post-operative radiation.

Verdict

Investors backed this company's Series B+ round based on the clear clinical utility and immediate patient benefit of GammaTile, not the potential for expansive market disruption. They implicitly bet on accelerated adoption within a specific neurosurgical niche due to demonstrated improvements in local tumor control and reduced systemic radiation exposure. The upside was inherently limited by the narrow application within brain tumor treatment, contrasting with broader oncology platforms that address multiple cancer types.

Source: SEC EDGAR Form D filing